Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06662825 · ClinicalTrials.gov registry record
Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell Centers
A clinical trial, sponsored by Novartis.
- Completed
- Registry status
- 376
- Enrollment target
NCT06662825 is a clinical trial that has completed, run by Novartis. The registered enrollment target is 376 participants.
The verdict
NCT06662825 has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- 376 participants
- Enrollment target
Study Summary
This was a retrospective cohort study using secondary data from member sites of the National Alliance of Sickle Cell Centers (NASCC) with patients who had initiated crizanlizumab between 2019 and 2022.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2022-12-13 |
| Est. Completion | 2023-11-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06662825
The ClinicalTrials.gov registry entry for NCT06662825 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 376 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06662825 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06662825 about?
NCT06662825 is a clinical study titled "Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell Centers". This was a retrospective cohort study using secondary data from member sites of the National Alliance of Sickle Cell Centers (NASCC) with patients who had initiated crizanlizumab between 2019 and 2022.
What is the current status of trial NCT06662825?
This trial is currently completed. The enrollment target is 376 participants. The study started on 2022-12-13. Estimated completion is 2023-11-01.
Who is sponsoring clinical trial NCT06662825?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.